[Favorable effects of decreasing lipids in patients with diabetes mellitus].
Patients with diabetes mellitus are patients at high risk for cardiovascular events. There is only limited number of studies examining the effects of lipid lowering specifically in diabetics. The majority of evidence is derived from subgroup analyses of large intervention trials. Patients with diabetes mellitus benefit from a therapy with statins, independently from the starting LDL cholesterol concentrations. Furthermore, recent studies strongly suggest that for high risk patients such as diabetics regarding LDL "the lower is the better" The data for the benefits of fibrate therapy is not as robust as those available for statins. Therefore, at present no specific recommendation for treatment of diabetics with fibrates can be made.
Gouni-Berthold
I
I
Klinik II und Poliklinik für Innere Medizin der Universität zu Köln, Köln, Germany. ioanna.berthold@uni-koeln.de
Krone
W
W
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002995:Clofibric Acid / Q000009:adverse effects / Q000627:therapeutic use; D048909:Diabetes Complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002995:Clofibric Acid